slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Drug and Therapeutics Committee PowerPoint Presentation
Download Presentation
Drug and Therapeutics Committee

Loading in 2 Seconds...

play fullscreen
1 / 27

Drug and Therapeutics Committee - PowerPoint PPT Presentation


  • 388 Views
  • Uploaded on

Drug and Therapeutics Committee. Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines Perform ABC analysis and explain how it can be used to identify medicine use problems, reduce cost, and improve efficiency in the pharmaceutical supply system

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

Drug and Therapeutics Committee


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
    Presentation Transcript
    1. Drug and Therapeutics Committee

    2. Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines Perform ABC analysis and explain how it can be used to identify medicine use problems, reduce cost, and improve efficiency in the pharmaceutical supply system Discuss how VEN system for setting priorities will assist the DTC in medicine selection, purchasing, and inventory management Objectives

    3. Introduction Aggregate data DDD VENABC Analysis Activities 3–5 Summary Outline—Part B

    4. Indicator study methods Use data collected at the individual level—patient, health facility Data insufficient to make judgments about appropriateness of a medicine for a specific diagnosis Aggregate data methods Use routine data (e.g., stock records) not collected at the individual patient level Gives overview of medicine use and can highlight problem areas In-depth investigation of medicine use Prescription audit, patient record review Drug use evaluation (DUE) (discussed in session 11) Qualitative methods to understand causes of a medicine use problem (discussed in session 8) Methods to Investigate Medicine Use

    5. Medicine use aggregate data sources Procurement records Warehouse medicine records Pharmacy stock and dispensing records Adverse drug reaction (ADR) and medication error reports Patient medical records Aggregate Data (1)

    6. Data that can be retrieved Medicine consumption Medicine availability Medicine cost data Frequency of use Per capita use of specific product Prevalence of ADRs Prevalence of medication errors Aggregate Data (2)

    7. The DDD methodology converts and standardizes readily available product quantity data, such as packages, tablets, injection vials, bottles, into crude estimates of clinical exposure to medicines, such as the number of daily doses A methodology that allows comparison of consumption of pharmaceutical products across hospitals, regions, and countries Combines different medicine strengths and doses to provide one unit of consumption for each medicine for comparison of use Defined Daily Dose (1)

    8. Defined globally by the WHO Collaborating Center for Drug Statistics Methodology, Oslo, Norway http://www.whocc.no/atcddd/ Typically expressed as follows DDD per 1,000 inhabitant per day for total medicine consumption DDD per 100 beds per day (100 bed-days), for hospital use Defined Daily Dose (2)

    9. District hospital and clinics use of captopril with 2,700,000 population 22,500,000 tablets yearly of captopril 25 mg 3,000,000 tablets yearly of captopril 50 mg Quantity of medicine used in 1 year multiplied by strength of the product = (22,500,000 × 25 mg) + (3,000,000 × 50 mg) = 712,500,000 mg Divide total quantity by assigned DDD for that medicine (captopril = 50 mg ) = 712,500,000 / 50 mg = 14,250,000 DDDs Divide total quantity by 2,700,000 population and multiply by 1,000 (this is the population denominator for this method) = (14,250,000 / 2,700,000 ) x 1,000 inhabitants = 5,278 DDD / 1,000 inhabitants / year 5,278 / 365 = 14.5 DDD / 1,000 inhabitants / day Defined Daily Dose Example 1: Captopril

    10. Annual consumption = 100 million x 200 mg tablets = 20,000,000,000 mg = 20,000,000 g Assigned DDD for carbamazepine = 1 g No. DDDs consumed = 20,000,000/1 = 20,000,000 per year = 20,000,000/365 = 54,795 per day for population of 48,000,000 = 54,795 / 48,000,000 = 0.0011 per person per day = 1.1 DDD per 1,000 population per day Defined Daily Dose Example 2:Carbamazepine Use in South Africa, 2001

    11. Method to prioritize for medicine purchase and stock V–Vital Potentially lifesaving Crucial to providing basic health services E–Essential Effective against less severe but significant illness, but not vital N–Nonessential For minor illnesses High cost and low therapeutic advantage VEN Analysis

    12. Step 1. Classify all medicine on the list as V, E, or N. Step 2. Analyze the “N” items. Where possible, reduce quantities to purchase or eliminate them. Step 3. Identify and limit therapeutic duplications. Step 4. Reconsider proposed purchase quantities. Step 5. Find additional funds if needed or possible. Conducting a VEN Analysis

    13. Identifies high-priority medicines for procurement Identifies low-priority medicines that the DTC should analyze carefully for deletion from the formulary VEN Applications for DTC

    14. Description VEN 1 AMOXYCILLIN CAPSULES PATIENT READY PACK;250MG;15'S 2 AMPHOTERICIN B FOR INJECTIONINTRAVENOUS;50MG 3 BECLOMETHASONE DIPROPIONATE INHALER;50MCG/DOSE;200 DOSES 4 CARBAMAZEPINE 200MG TABLET;PATIENT READY PACK;84'S 5 CHLORHEXIDINE GLUCONATE DETERGENT SOLUTION4%;SURGICAL SCRUB;500ML 6 CLOXACILLIN SODIUM FOR INJECTION500MG 7 CO-TRIMOXAZOLE 480mg TABLETS PATIENT READY PACK;20'S 8 DIAZEPAM TABLETS 5MG ;1000'S 9 ETHAMBUTOL,RIFAMPICIN,ISONIAZID AND PYRAZINAMIDE TABLETS:225/120/60/300MG;100'S 10 GENTAMICIN SULPHATE INJECTION80MG/2ML;2ML 11 IBUPROFEN SUSPENSION:PAEDIATRIC;100MG/5ML;100ML 12 INSULIN INJECTION:HUMAN;SOLUBLE 30%;ISOPHANE 70%;100IU/ML;10ML 13 ISONIAZID AND THIACETAZONE TABLETS 133MG AND 50MG;1000'S 14 LITHIUM CARBONATE TABLETS 250MG; 1000'S 15 LOPERAMIDE 2MG TABLETS;6'S 16 MERCUROCHROME SOLUTION; 1%; DROPPER BOTTLE; 20ML 17 NUR-ISTERATE:NORETHISTERONE ENANTATE INJECTION LONG-ACTING;200MG/ML;1ML 18 PARACETAMOL AND CODEINE TABLETS500MG;8MG;20'S 19 PARACETAMOL TABLETS 500MG;500'S 20 PERINDOPRIL TABLET 4MG;28'S 21 RESERPINE TABLETS PATIENT READY PACKS;0,25MG;14'S 22 TEST STRIPS AND COLOR CHART,GLUCOSE IN BLOOD ACCUTREND;50'S 23 THIOPENTONE SODIUM INJECTION 0.5G/20ML;W/OUT DILUENT;MIXER VIAL;20ML 24 VACCINE POLIOMYELITIS;ORAL TRIVALENT;10 DOSE 25 VITAMIN B6 TABLETS 25MG;500'S 26 WATER FOR INJECTION PLASTIC;10ML VEN Analysis, Activity, and Discussion

    15. Method for determining and comparing pharmaceutical costs within the formulary system “Separating the vital few from the trivial many”— Pareto principle Tool for identifying many medicine use problems Utilizes computer and appropriate software to run analysis ABC Analysis

    16. ABC Analysis: A, B, and C Medicines (1) Percentage of Percentage of Category Budget Medicines Ordered A medicines 70–80% 10–20% B medicines 15–20% 10–20% C medicines 5–10% 60–80%

    17. A medicines—High percentage of funds spent on large-volume or high-cost items Greatest potential for savings Greatest potential for identifying expensive medicines that are overused B medicines—Moderate cost and moderate number of items; important items C medicines—Small amount of funds spent on the majority of the inventory ABC Analysis: A, B, and C Medicines (2)

    18. Measures the degree to which actual consumption reflects public health needs and morbidity Reduces inventory levels and costs by arranging for more frequent purchase or delivery of smaller quantities of class A items Seeks major cost reductions by finding lower prices on class A items Reduces inventory of items that have limited use in the system, but costs the system large amounts of money Provides information for choosing the most cost-effective alternatives and finding opportunities for therapeutic substitution Gathers information for pharmacoeconomic analysis Applications of ABC Analysis for a DTC

    19. Step 1. List all items purchased and enter the unit cost. Step 2. Enter consumption quantities for each item. Step 3. Calculate the value of consumption for each item. Step 4. Sort the list in descending order by total value. Step 5. Calculate the percentage of total value represented by each item. Step 6. Calculate the cumulative percentage of total value for each item. Step 7. Choose cutoff points for A, B, and C. Steps in Performing ABC Analysis

    20. ABC Step 1. List items and unit costs.

    21. ABC Steps 2 and 3. Calculate consumption quantities and values—sort list by descending values.

    22. ABC Step 4. Calculate the percentage of total value represented by each item.

    23. ABC Step 5. Rank items in descending order.

    24. ABC Step 6. Calculate the cumulative percentage of total value for each item.

    25. 100% 90% 80% 70% 60% Cumulative Items Value (%) 50% 40% 30% 20% 10% 0% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 55% 60% 65% 70% 75% 80% 85% 90% 95% Cumulative No. of Items (%) ABC Step 7. Choose cut-off points for ABC analysis chart.

    26. Activity 3. VEN Analysis—Performing a VEN analysis Activity 4. Performing an ABC analysis—Identifying high-cost medicines using an ABC analysis Activity 5. Performing an ABC/VEN analysis using participants’ data Activities 3, 4, and 5

    27. A major function of a DTC is to identify medicine use problems and to implement corrective measures Aggregate methods are a useful way to gain an overview of medicine use problems using routine data not collected at the individual patient level. Examples of a aggregate data methods include— DDD VEN analysis ABC analysis Summary